Evidence map›Paper›PMID 40236411›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Integrating Pulmonary and Systemic Transcriptomic Profiles to Characterize Lung Injury after Pediatric Hematopoietic Stem Cell Transplant.

Emma M Pearce, Erica Evans, Madeline Y Mayday, Gustavo Reyes, Miriam R Simon, Jacob Blum, Hanna Kim, Jessica Mu, Peter J Shaw, Courtney M Rowan and 28 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors.

Emma M PearceDivision of Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Erica EvansDivision of Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Madeline Y MaydayDivision of Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Gustavo ReyesDivision of Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Miriam R SimonDivision of Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Jacob BlumDivision of Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Hanna KimDivision of Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Jessica MuDivision of Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Peter J ShawThe Children`s Hospital at Westmead, Westmead, NSW, Australia.
Courtney M RowanIndiana University, Department of Pediatrics, Division of Critical Care Medicine, Indianapolis, IN, USA.
Jeffrey J AulettaHematology/Oncology/BMT and Infectious Diseases, Nationwide Children's Hospital, Columbus, OH, USA.
Paul L MartinDivision of Pediatric and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
Caitlin HurleyDivision of Critical Care, Department of Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Erin M KremlDepartment of Child Health, Division of Critical Care Medicine, University of Arizona, Phoenix, AZ, USA.
Muna QayedAflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, GA, USA.
Hisham Abdel-AzimDepartment of Pediatrics, Division of Hematology/Oncology and Transplant and Cell Therapy, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Amy K KeatingHarvard Medical School, Boston, Massachusetts; Division of Pediatric Oncology, Department of Pediatrics, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA, USA.
Geoffrey D E CuvelierCancerCare Manitoba, Manitoba Blood and Marrow Transplant Program, University of Manitoba, Winnipeg, Manitoba, Canada.
Janet R HumeUniversity of Minnesota, Department of Pediatrics, Division of Critical Care Medicine, Minneapolis, MN, USA.
James S KillingerDivision of Pediatric Critical Care, Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA.
Kamar GodderCancer and Blood Disorders Center, Nicklaus Children's Hospital, Miami, FL, USA.
Rabi HannaDepartment of Pediatric Hematology, Oncology and Blood and Marrow Transplantation, Pediatric Institute, Cleveland Clinic, Cleveland, OH, USA.
Christine N DuncanHarvard Medical School, Boston, Massachusetts; Division of Pediatric Oncology, Department of Pediatrics, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA, USA.
Troy C QuiggPediatric Blood and Marrow Transplantation Program, Texas Transplant Institute, Methodist Children's Hospital, San Antonio, TX, USA.
Paul CastilloUniversity of Florida, Gainesville, UF Health Shands Children's Hospital, Gainesville, FL, USA.
Nahal R LalefarDivision of Pediatric Hematology/Oncology, UCSF Benioff Children's Hospital Oakland, University of California San Francisco, Oakland, CA, USA.
Julie C FitzgeraldDepartment of Anesthesiology and Critical Care, Perelman School of Medicine, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.
Kris M MahadeoDepartment of Pediatrics, Division of Hematology/Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Prakash SatwaniDivision of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, Columbia University, New York, NY, USA.
Theodore B MooreDepartment of Pediatric Hematology-Oncology, Mattel Children's Hospital, University of California, Los Angeles, CA, USA.
Benjamin HanischChildren's National Hospital, Washington, District of Columbia, USA.
Aly Abdel-MageedSection of Pediatric BMT and Cellular Therapy, Helen DeVos Children's Hospital, Grand Rapids, MI, USA.
Dereck B DavisDepartment of Pediatrics, Hematology/Oncology, University of Mississippi Medical Center, Jackson, MS, USA.
Michelle P HudspethAdult and Pediatric Blood & Marrow Transplantation, Pediatric Hematology/Oncology, Medical University of South Carolina Children's Hospital/Hollings Cancer Center, Charleston, SC, USA.
Greg A YanikPediatric Blood and Bone Marrow Transplantation, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
Michael A PulsipherDivision of Pediatric Hematology and Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT, USA.
Christopher C Joseph L DvorakDivision of Allergy, Immunology, and Bone Marrow Transplantation, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Matt S ZinterDivision of Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-3351-3278

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Pediatric Scientist Development Program (PSDP) [K12]K12HD000850 · NICHD · YALE UNIVERSITY · PI Sallie R. Permar · 1987 to 2026
$44.1M
Unrelated Donor BMT vs. Immune Suppression for Newly Diagnosed Severe Aplastic Anemia in Children and Young Adults: BMT CTN Core Center Renewal for the Pediatric Blood and Marrow Transplant ConsortiumUG1HL069254 · NHLBI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S · 2017 to 2023
$1.3M
Pathobiologic Transcriptional Signatures of Pulmonary Complications in Pediatric Hematopoietic Cellular TransplantationK23HL146936 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZINTER, MATTHEW SCOTT · 2020 to 2024
$980k
Investigation of pulmonary fibrosis biology in pediatric hematopoietic cell transplant patientsR03HL171423 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZINTER, MATTHEW SCOTT · 2024 to 2025
$253k
Elucidation of the molecular mechanisms of the RBM15-MKL1 fusion protein in acute megakaryoblastic leukemiaF31CA271571 · NCI · YALE UNIVERSITY · PI Madeline Young Mayday · 2023 to 2026
$155k
NCI NIH HHS F31 CA271571NCI NIH HHS P30 CA008748NHLBI NIH HHS K23 HL146936NHLBI NIH HHS R03 HL171423NHLBI NIH HHS UG1 HL069254NICHD NIH HHS K12 HD000850
6 · The paper itself

Abstract

Hematopoietic stem cell transplantation (HCT) is potentially curative for numerous malignant and non-malignant diseases but can lead to lung injury due to chemoradiation toxicity, infection, and immune dysregulation. Bronchoalveolar lavage (BAL) is the most commonly used procedure for diagnostic sampling of the lung but is invasive, cannot be performed in medically fragile patients, and is challenging to perform serially. We previously showed that BAL transcriptomes representing pulmonary inflammation and cellular injury can phenotype post-HCT lung injury and predict mortality outcomes. However, whether peripheral blood testing is a suitable minimally-invasive surrogate for pulmonary sampling in the HCT population remains unknown. To address this question, we compared 210 paired BAL and peripheral blood transcriptomes obtained from 166 pediatric HCT patients at 27 children's hospitals. BAL and blood mRNA abundance showed minimal overall correlation at the level of individual genes, gene set enrichment scores, imputed cell fractions, and T- and B-cell receptor clonotypes. Instead, we identified significant site-specific transcriptional programs. In BAL, expression of innate and adaptive immune pathways was tightly co-regulated with expression of epithelial mesenchymal transition and hypoxia pathways, and these signatures were associated with mortality. In contrast, in blood, expression of endothelial injury, DNA repair, and cellular metabolism pathways was associated with mortality. Integration of paired BAL and blood transcriptomes dichotomized patients into two groups, of which one group showed twice the rate of hypoxia and significantly worse outcomes within 7 days of enrollment. These findings reveal a compartmentalized injury response, where BAL and peripheral blood transcriptomes provide distinct but complementary insights into local and systemic mechanisms of post-HCT lung injury.

Identifiers

PMID40236411
PMCPMC11998824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.